TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

• Status: Recruiting
• Trial end date: 2024-11-15
• Target enrollment: 0
• Participant gender: All

Summary

REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. All patients will be followed up for up to 3 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
• Treatments: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carvedilol; Metoprolol

Criteria

Inclusion Criteria:

• ≥18 years old

• Admitted for STEMI or NSTEMI and invasive management (i.e. coronary angiography during index hospitalization).

• LVEF>40% as evaluated by any imaging technique anytime during hospitalization.

• Signed informed consent

Exclusion Criteria:

• Known allergy or intolerance to beta-blockers

• Absolute contraindication to beta-blocker therapy according to treating physician judge

• Prior history of HF, Killip class on admission or during hospitalization ≥ II

• Severe valvular heart disease (> 3+ for aortic or mitral insufficiency, aortic or mitral valve area ≤1.0 cm2).

• Any condition (appart from AMI) that requires beta-blocker prescription on discharge according to treating physician judge

• Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year),

• Patients participating in other clinical trials